Alzheimer Disease Clinical Trial
Official title:
Real-world and Innovative Multimodal Prediction and Prevention of Postoperative Mortality and Multi-morbidities
This study will contribute to creating a prospective and robust automated preoperative risk assessment algorithm for 30-day mortality, major adverse cardiac and cerebrovascular events (MACCE) and perioperative neurocognitive disorders (PND) outcomes following elective general, orthopedic, cardiac, or vascular surgery. It will help to identify correlations between perioperative factors and Alzheimer's Disease (AD) or AD-related dementias (ADRD). Lastly, this study will create effective, validated multi-modal interventions to improve perioperative health. This study will explore two main hypotheses: 1. Preoperative prehabilitation and proactive cognitive/behavioral interventions will effectively improve postoperative cognitive outcomes, morbidities, and mortality, and; 2. The proactive bundled interventions are superior to current standard of care in reducing postoperative cognitive outcomes, MACCE and mortality. Expected Outcome: Improved EHR algorithm will have higher predictive accuracy for MACCE and mortality while predicting postoperative cognitive outcomes.
Status | Not yet recruiting |
Enrollment | 1200 |
Est. completion date | September 1, 2025 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Part I Inclusion Criteria: - 65 years of age and older - Identified as higher risk (=2.5%) for 30-day mortality and MACCE based on the UPMC's Perioperative Model (EHR risk prediction algorithm) - Scheduled for major cardiac surgeries including coronary artery bypass and valvular repair and/or vascular surgeries including carotid endarterectomy, aortic aneurysm repair, and major vascular surgeries - RAI score = 30 - PHQ-9 score = 5 - Anticipated length of stay > 3 days - Informed consent - English speaking patients - All races and ethnicities - Diverse background (education, area deprivation index) Part II Inclusion Criteria: - Patients undergoing high-risk cardiac and vascular surgery, such as intraoperative bypass for cardiac surgeries and carotid endarterectomy/ aortic aneurysm vascular surgeries. - History of fully resolved stroke and TIA without any residual weakness - Significant carotid artery stenosis (defined as >70% unilateral or bilateral stenosis) - Moderate and high risk for mortality based on Society of Thoracic Surgery score (score >4) - Enrolled in Part 1, "Randomized controlled clinical trial to assess the effectiveness of preoperative personalized prehabilitation as well as cognitive and behavioral interventions on reducing postoperative delirium (POD), postoperative cognitive dysfunction (POCD), dementia, 30-day major adverse cardiac and cerebrovascular events (MACCE) and mortality in high-risk surgical patients (=65y)." Part I Exclusion Criteria: - Children (<18 years) - Patients unable to provide consent - MoCA score <23 - Persistent weakness from prior cerebrovascular accident - Patients with severe preoperative medical diseases, blindness or significant visual impairment, unresolved motor weakness, or any other perioperative events or complications that would have a bearing on the patients' ability to perform study tasks, neuropsychological tests and proposed interventions Part II Exclusion Criteria: - Pregnant women - Patients do not provide consent. - Patients are unable to participate in cognitive and other behavioral assessment due to physical limitations - Patients refuse any blood transfusions during surgery |
Country | Name | City | State |
---|---|---|---|
United States | UPMC Presbyterian Hospital | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pittsburgh | National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cognitive Outcomes - Dementia | Clinical Dementia Rating Instrument (CDR) will be used to assess dementia. Ratings are as follows: 0 = none, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe | Preoperative baseline screening | |
Primary | Cognitive Outcomes - Dementia | Clinical Dementia Rating Instrument (CDR) will be used to assess dementia. Ratings are as follows: 0 = none, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe | At time of hospital discharge (up to day 5) | |
Primary | Cognitive Outcomes - Dementia | Clinical Dementia Rating Instrument (CDR) will be used to assess dementia. Ratings are as follows: 0 = none, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe | Postoperative 1-month | |
Primary | Cognitive Outcomes - Dementia | Clinical Dementia Rating Instrument (CDR) will be used to assess dementia. Ratings are as follows: 0 = none, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe | Postoperative 3-months | |
Primary | Cognitive Outcomes - Dementia | Clinical Dementia Rating Instrument (CDR) will be used to assess dementia. Ratings are as follows: 0 = none, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe | Postoperative 6-months | |
Primary | Cognitive Outcomes - Dementia | Clinical Dementia Rating Instrument (CDR) will be used to assess dementia. Ratings are as follows: 0 = none, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe | Postoperative 12-months | |
Primary | Cognitive Outcomes - Delirium | The long CAM-Severity will be used to assess delirium. For a diagnosis of delirium by CAM, the subject must display: 1. Presence of acute onset and fluctuating discourse AND 2. Inattention AND EITHER 3. Disorganized thinking OR 4. Altered level of consciousness. Subjects will be reported as yes/no for delirium. | Preoperative baseline screening | |
Primary | Cognitive Outcomes - Delirium | The long CAM-Severity will be used to assess delirium. For a diagnosis of delirium by CAM, the subject must display: 1. Presence of acute onset and fluctuating discourse AND 2. Inattention AND EITHER 3. Disorganized thinking OR 4. Altered level of consciousness. Subjects will be reported as yes/no for delirium. | At time of hospital discharge (up to day 5) | |
Primary | Cognitive Outcomes - Delirium | The long CAM-Severity will be used to assess delirium. For a diagnosis of delirium by CAM, the subject must display: 1. Presence of acute onset and fluctuating discourse AND 2. Inattention AND EITHER 3. Disorganized thinking OR 4. Altered level of consciousness. Subjects will be reported as yes/no for delirium. | Postoperative 1-month | |
Primary | Cognitive Outcomes - Delirium | The long CAM-Severity will be used to assess delirium. For a diagnosis of delirium by CAM, the subject must display: 1. Presence of acute onset and fluctuating discourse AND 2. Inattention AND EITHER 3. Disorganized thinking OR 4. Altered level of consciousness. Subjects will be reported as yes/no for delirium. | Postoperative 3-months | |
Primary | Cognitive Outcomes - Delirium | The long CAM-Severity will be used to assess delirium. For a diagnosis of delirium by CAM, the subject must display: 1. Presence of acute onset and fluctuating discourse AND 2. Inattention AND EITHER 3. Disorganized thinking OR 4. Altered level of consciousness. Subjects will be reported as yes/no for delirium. | Postoperative 6-months | |
Primary | Cognitive Outcomes - Delirium | The long CAM-Severity will be used to assess delirium. For a diagnosis of delirium by CAM, the subject must display: 1. Presence of acute onset and fluctuating discourse AND 2. Inattention AND EITHER 3. Disorganized thinking OR 4. Altered level of consciousness. Subjects will be reported as yes/no for delirium. | Postoperative 12-months | |
Primary | Cognitive Outcomes - Cognitive Function | The Montreal Cognitive Assessment (MoCA) will be used to assess cognitive functioning. A normal score is considered >/= 26 out of 30 total points. | Preoperative baseline screening | |
Primary | Cognitive Outcomes - Cognitive Function | The Montreal Cognitive Assessment (MoCA) will be used to assess cognitive functioning. A normal score is considered >/= 26 out of 30 total points. | At time of hospital discharge (up to day 5) | |
Primary | Cognitive Outcomes - Cognitive Function | The Montreal Cognitive Assessment (MoCA) will be used to assess cognitive functioning. A normal score is considered >/= 26 out of 30 total points. | Postoperative 1-month | |
Primary | Cognitive Outcomes - Cognitive Function | The Montreal Cognitive Assessment (MoCA) will be used to assess cognitive functioning. A normal score is considered >/= 26 out of 30 total points. | Postoperative 3-months | |
Primary | Cognitive Outcomes - Cognitive Function | The Montreal Cognitive Assessment (MoCA) will be used to assess cognitive functioning. A normal score is considered >/= 26 out of 30 total points. | Postoperative 6-months | |
Primary | Cognitive Outcomes - Cognitive Function | The Montreal Cognitive Assessment (MoCA) will be used to assess cognitive functioning. A normal score is considered >/= 26 out of 30 total points. | Postoperative 12-months | |
Secondary | Cognitive Outcomes - Depression | Patient Health Questionnaire (PHQ-9) will be used to assess depression. Scoring is as follows: 1-4 = minimal depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, and 20-27 = severe depression | Preoperative baseline screening | |
Secondary | Cognitive Outcomes - Depression | Patient Health Questionnaire (PHQ-9) will be used to assess depression. Scoring is as follows: 1-4 = minimal depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, and 20-27 = severe depression | At time of hospital discharge (up to day 5) | |
Secondary | Cognitive Outcomes - Depression | Patient Health Questionnaire (PHQ-9) will be used to assess depression. Scoring is as follows: 1-4 = minimal depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, and 20-27 = severe depression | Postoperative 1-month | |
Secondary | Cognitive Outcomes - Depression | Patient Health Questionnaire (PHQ-9) will be used to assess depression. Scoring is as follows: 1-4 = minimal depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, and 20-27 = severe depression | Postoperative 3-months | |
Secondary | Cognitive Outcomes - Depression | Patient Health Questionnaire (PHQ-9) will be used to assess depression. Scoring is as follows: 1-4 = minimal depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, and 20-27 = severe depression | Postoperative 6-months | |
Secondary | Cognitive Outcomes - Depression | Patient Health Questionnaire (PHQ-9) will be used to assess depression. Scoring is as follows: 1-4 = minimal depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, and 20-27 = severe depression | Postoperative 12-months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |